GlassScriptPhysician profile
Kavitha Subramanian
NPI 1174661110
$8,559.54
in general payments reported to CMS, 2019-2025
42 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,414 · 2020: $1,532 · 2021: $1,893 · 2022: $1,646 · 2023: $744 · 2024: $645 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,632.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $956.19 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $753.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $537.94 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $505.91 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $468.48 | 2019-2025 | Otezla, Repatha |
| Abbvie INC. | $426.03 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Esperion Therapeutics, INC. | $388.16 | 2020-2023 | Nexletol |
| Pfizer INC. | $277.24 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $250.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $243.54 | 2019-2023 | |
| Amarin Pharma, INC. | $236.68 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $193.76 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $186.77 | 2019-2023 | Gardasil 9, Proquad, Vaxelis |
| Teva Pharmaceuticals USA, INC. | $117.12 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.